Sensorion Receives Positive Recommendation From Data Monitoring Committee Of SENS-501’s Audiogene Phase 1/2 Clinical Trial - Medical Device News Magazine

Medical Device News Magazine

Factuality

Ownership

Sensorion Receives Positive Recommendation From Data Monitoring Committee Of SENS-501’s Audiogene Phase 1/2 Clinical Trial - Medical Device News Magazine

The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric patients aged between 6 and 31 months at the time of gene therapy treatment. By targeting the first years of life, when brain plasticity is at its peak, the chances of these young children with pre-linguistic hearing loss of acquiring normal speech and languag…